Revenue Recognition Revenue Recognition (Tables)

9 Months Ended

Mar. 31, 2020

Disaggregation of Revenue [Line Items]

The following table allocates revenue by the location where the goods were made or the service performed:


(Dollars in millions)	Three Months Ended March 31, 2020		Three Months Ended March 31, 2019		Nine Months Ended March 31, 2020		Nine Months Ended March 31, 2019

United States	$	438.9	$	318.4	$	1,215.9	$	913.9
Europe	258.7		200.8		690.1		609.9
International Other	83.5		108.2		299.8		321.6
Elimination of revenue attributable to multiple locations	(20.5)		(9.9)		(59.1)		(53.1)
Total	$	760.6	$	617.5	$	2,146.7	$	1,792.3

Product and Service[Member]

Disaggregation of Revenue [Line Items]

Disaggregation of Revenue

The following tables allocate revenue, for the three and nine months ended March 31, 2020 and March 31, 2019, by type of activity and reporting segment (in millions):


Three Months Ended March 31, 2020	Softgel & Oral Technologies		Biologics		Oral & Specialty Delivery		Clinical Supply Services		Total
Manufacturing & commercial product supply	$	217.6	$	85.2	$	127.2	$	—	$	430.0
Development services	24.7		164.8		54.2		—		243.7
Clinical supply services	—		—		—		88.9		88.9
Total	$	242.3	$	250.0	$	181.4	$	88.9	$	762.6
			Inter-segment revenue elimination										(2.0)
					Combined net revenue						$	760.6


Three Months Ended March 31, 2019	Softgel & Oral Technologies		Biologics		Oral & Specialty Delivery		Clinical Supply Services		Total
Manufacturing & commercial product supply	$	232.9	$	66.8	$	99.7	$	—	$	399.4
Development services	21.1		66.9		54.1		—		142.1
Clinical supply services	—		—		—		77.8		77.8
Total	$	254.0	$	133.7	$	153.8	$	77.8	$	619.3
			Inter-segment revenue elimination										(1.8)
					Combined net revenue						$	617.5


Nine Months Ended March 31, 2020	Softgel & Oral Technologies		Biologics		Oral & Specialty Delivery		Clinical Supply Services		Total
Manufacturing & commercial product supply	$	701.5	$	229.6	$	294.5	$	—	$	1,225.6
Development services	69.3		434.2		162.7		—		666.2
Clinical supply services	—		—		—		261.4		261.4
Total	$	770.8	$	663.8	$	457.2	$	261.4	$	2,153.2
			Inter-segment revenue elimination										(6.5)
					Combined net revenue						$	2,146.7


Nine Months Ended March 31, 2019	Softgel & Oral Technologies		Biologics		Oral & Specialty Delivery		Clinical Supply Services		Total
Manufacturing & commercial product supply	$	680.8	$	168.1	$	262.4	$	—	$	1,111.3
Development services	67.7		227.7		156.7		—		452.1
Clinical supply services	—		—		—		236.3		236.3
Total	$	748.5	$	395.8	$	419.1	$	236.3	$	1,799.7
			Inter-segment revenue elimination										(7.4)
					Combined net revenue						$	1,792.3